Table 1.
Characteristics of studies that used a symptom assessment scale in pediatric oncology
| Author | Year | Instrument | Mean age in years ±SD or (range) | Number enrolled | Respondent | Timing ** | Once or multiple *** |
|---|---|---|---|---|---|---|---|
| Baggott[18] |
2011 |
MSAS 10-18 |
14.7 ± 2.8 |
66 |
Child |
During |
Multiple |
| Wu[19] |
2011 |
SDS |
NS |
40 |
Child |
During |
Once |
| Gibson[16] |
2010 |
ASyMS-YG |
15* (13–18) |
27 |
Child |
During |
Multiple |
| Poder[3] |
2010 |
MSAS 10-18 |
NS |
292 |
Parent |
During |
Multiple |
| Walker[20] |
2010 |
MSAS 7-12 |
14.2 + 2.7 |
51 |
Child |
During |
Multiple |
| Dupuis[17] |
2009 |
Unique |
9.4 ± 6.8 |
200 |
Parent |
During |
Once |
| Sitaresmi[21] |
2009 |
Unique |
6* (2–16) |
61 |
Parent |
During |
Once |
| Yeh[22] |
2009 |
MSAS 10-18 |
14.2 + 2.2 |
144 |
Parent |
Both |
Once |
| Williams[23] |
2006 |
TRSC-C |
10.4 ± 6.1 |
11 |
Parent |
During |
Once |
| Collins[24] |
2002 |
MSAS 7-12 |
9.6 (7–12) |
149 |
Child |
Both |
Multiple |
| Hinds[25] |
2002 |
SDS |
15.5 ± 2.1 |
77 |
Child |
During |
Multiple |
| Collins[26] |
2000 |
MSAS 10-18 |
14 (10–18.2) |
160 |
Child |
Both |
Multiple |
| Berard[27] |
1998 |
RSCL |
16.9 |
43 |
Child |
During |
Multiple |
| Eiser[28] | 1997 | RSCL | 14.5 (4–19) | 47 | Parent | Both | Once |
*Median; **Timing refers to whether instrument was administered during active treatment only or both during and following completion of chemotherapy; ***Instrument administered once or more than once.
Abbreviations: ASyMS-YG Advanced Symptom Management System – Young, MSAS Memorial Symptom Assessment Scale, SDS Symptom Distress Scale, TRS-C Therapy-related Symptom Checklist, RSCL Rotterdam Symptom Checklist, SD standard deviation, NS not stated.